6533b861fe1ef96bd12c4568

RESEARCH PRODUCT

Ra223 in bone metastases with osteolytic activity

Renato CostaDavide CardileFrancesco VerderameVincenzo TripoliAlessandra Murabito

subject

Radium-223lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyOsteolysislcsh:R895-920Case ReportScintigraphy030218 nuclear medicine & medical imagingradium 22303 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancerosteoblastic bone metastasesmedicineIn patientRadium-223 Dichlorideosteolytic bone metastasesmedicine.diagnostic_testbusiness.industryBone metastasesTherapeutic effectmedicine.disease030220 oncology & carcinogenesisRadiologybusinessmedicine.drug

description

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development for this radiopharmaceutical.

yearjournalcountryeditionlanguage
2018-04-01World Journal of Nuclear Medicine
10.4103/wjnm.wjnm_22_17http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=2;spage=116;epage=119;aulast=Costa